Compare CSTL & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | PEB |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 2019 | 2009 |
| Metric | CSTL | PEB |
|---|---|---|
| Price | $40.31 | $12.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | ★ $46.00 | $12.35 |
| AVG Volume (30 Days) | 331.6K | ★ 2.1M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $343,530,000.00 | ★ $1,464,126,000.00 |
| Revenue This Year | $2.54 | $2.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.15 | 0.99 |
| 52 Week Low | $14.59 | $7.42 |
| 52 Week High | $42.18 | $14.21 |
| Indicator | CSTL | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 63.55 |
| Support Level | $38.73 | $12.01 |
| Resistance Level | $41.60 | $12.95 |
| Average True Range (ATR) | 1.58 | 0.42 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 62.75 | 64.66 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.